This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function — CVID Type IB-세포 수 및 기능의 현저한 이상에 의한 공통 가변성 면역결핍

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D83.0 (common variable immunodeficiency with predominant abnormalities of B-cell numbers and function) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsCommon Variable Immunodeficiency (CVID), acquired hypogammaglobulinemia, CVID with B-cell functional deficiency, CVID Type I
C. Adult onsetPossibility of first onset in adulthood: high — CVID is one of the most common primary immunodeficiencies first diagnosed in adulthood (20s–40s); it is typically discovered by serum Ig testing after recurrent pneumonia and sinusitis have persisted for several years.
1. HistoryAfter Bruton's description of agammaglobulinemia in 1953 → 1971: the CVID concept appears in the WHO classification → 1999: ESID/PAGID diagnostic criteria → 2016: revised ICON criteria. Classification of the B-cell number abnormality type (Type I) established.
2. CausesMostly a polygenic predisposition of unknown cause. Single-gene variants such as ICOS, TACI, BAFF-R, CD19, CD20, CD21, CD81, LRBA and CTLA-4 identified in a minority. Impaired B-cell differentiation and class switching is central.
3. GeneticsGenetically heterogeneous. A single-gene cause is identified in about 10–20%; TNFRSF13B (TACI), TNFRSF13C (BAFF-R), ICOS, etc. The rest presumed to be polygenic predisposition. Associated with the HLA-A1-B8-DR3 haplotype.
4. General epidemiologyAbout 1:25,000–1:50,000. One of the most common primary immunodeficiencies overall among CVID. Bimodal distribution (teens, 20s–30s). Similar in men and women. Relatively high prevalence in people of European ancestry.
5. PathophysiologyImpaired B-cell development — marked reduction of class-switched memory B cells → poor production of IgG/A/M → increased susceptibility to encapsulated bacteria (pneumococcus, Haemophilus influenzae).
6. SymptomsRecurrent sinopulmonary infections, pneumonia (pneumococcus, H. influenzae), chronic lung disease (bronchiectasis), gastrointestinal symptoms (diarrhea, malabsorption), autoimmune disease, granuloma formation, increased risk of malignancy (lymphoma, gastric cancer).
7. SignsSerum IgG <5 g/L + reduced IgA and/or IgM; marked reduction of switched memory B cells (CD27+IgD−IgM−); poor antibody response after vaccination; lymph node and spleen enlargement; bronchiectasis (chest CT).
8. ScreeningQuantification of serum IgG/A/M in adults with recurrent infections; antibody titers after vaccination; B-cell fraction (flow cytometry). Ig screening is essential in patients aged 4 or older with recurrent pneumonia or sinusitis.
9. DiagnosisIgG <5 g/L (or ≥2 SD below mean) + reduced IgA/IgM + poor vaccine response + age 4 or older + exclusion of secondary causes + B-cell fraction. ESID/ICON criteria applied.
10. TreatmentIgG replacement therapy (IVIG or SCIG) is the mainstay; target IgG maintenance level ≥700–800 mg/dL. Prophylactic antibiotics (when bronchiectasis is present). Autoimmune complications: steroids, rituximab, abatacept. Granulomas: steroids, azathioprine.
11. PrognosisSurvival improved greatly since the introduction of IVIG. Main causes of death: worsening bronchiectasis (chronic lung disease), lymphoma, hepatic complications. Poor prognosis with autoimmunity or granulomas. Early diagnosis and early treatment are important.
12. PreventionLive vaccines contraindicated; inactivated pneumococcal and influenza vaccines recommended; prevention of bacterial infections by continuing IVIG; regular assessment of lung function; monitoring for malignancy and autoimmunity.
13. ReferencesConley ME et al. Criteria for the diagnosis of primary antibody deficiencies … and 9 other papers

1. History

Common variable immunodeficiency (CVID) is one of the most common and clinically important primary antibody deficiencies, and its history unfolded in earnest after Ogden Bruton first described X-linked agammaglobulinemia (XLA) in 1953. In 1954, Eberhard Dunie and colleagues reported a case of acquired hypogammaglobulinemia in an adult male with reduction of all of IgG, IgA and IgM, which corresponds to the early description of today's CVID. Subsequently, through the 1960s–70s, differences between adult-onset and childhood-onset forms of gammaglobulinemia began to be recognized, and it was found that the forms of antibody deficiency presenting mainly in adults represent a more heterogeneous condition.

In 1971, the World Health Organization (WHO) formalized the term "common variable" in its report on the classification of primary immunodeficiencies. The name conveys that patients with diverse genetic and clinical backgrounds share the common phenotype of hypogammaglobulinemia and recurrent infections. In the 1980s–90s, the European Society for Immunodeficiencies (ESID) and the Pan-American Group for Immunodeficiency (PAGID) held discussions to formalize diagnostic criteria for CVID, and the ESID/PAGID consensus criteria published by Conley et al. in 1999 were an important achievement of this period. These criteria set reduced IgG, IgA and IgM, poor vaccine response, onset at age 4 or older and exclusion of secondary causes as the core elements.

In the ICD-10 system, CVID is classified as D83, and D83.0 is subdivided as CVID with predominant abnormalities of B-cell numbers and function (CVID Type I). This subtype includes patients in whom impaired development of B cells themselves (reduced B-cell numbers, loss of switched memory B cells) is identified as the main immunological abnormality. Since the 2000s, as variants in genes such as ICOS, TACI, BAFF-R, CD19, CD20, CD81, LRBA and CTLA-4 have been identified in some CVID patients, the molecular genetic understanding of CVID has advanced greatly. In 2016, the ICON (International Consensus Document) criteria were revised, establishing the latest guidelines for the diagnosis of CVID.

Epidemiological data on CVID in Korea are limited, but a small number of cases are accumulating through Health Insurance Review & Assessment Service (HIRA) data and registry studies by clinical immunology centers. Because CVID is one of the most common primary immunodeficiencies first diagnosed in adulthood, improving the diagnostic rate through early serum Ig testing in patients with recurrent pneumonia and sinusitis is an important clinical task.

2. Causes

The cause of the CVID D83.0 subtype is an abnormality of genes or molecules involved in B-cell development, maturation, class-switch recombination and memory B-cell formation, resulting in numerical and functional abnormalities of B cells and a marked reduction in serum immunoglobulin production. In most CVID patients, no clear single-gene cause is identified (about 80–90%), and a polygenic predisposition and environmental factors are presumed to be involved in combination.

A particularly notable immunological abnormality in the D83.0 subtype is a marked reduction of class-switched memory B cells (CD27+IgD−IgM−). Switched memory B cells are antigen-experienced B cells generated in the germinal center reaction and are responsible for rapid and efficient IgG and IgA antibody responses on reinfection. Loss of this cell population is the direct cause of recurrent infections and poor vaccine responses in CVID. The Freiburg classification (2003, Warnatz et al.) subtyped CVID by whether the switched memory B-cell fraction (≥0.4%) is reduced, and D83.0 corresponds to the group in this classification in which abnormal B-cell development is predominant.

Among known single-gene causes, loss-of-function variants in ICOS (inducible T-cell co-stimulator, 2q33.2) were the first single-gene cause of CVID identified (Grimbacher et al., 2003), and TACI (TNFRSF13B, 17p11.2), BAFF-R (TNFRSF13C, 22q13.2), CD19 (16p11.2), CD20 (11q12.2), CD81 (11p15.5), LRBA (4q31.3), CTLA-4 (2q33.2), PIK3CD (activating variants) and others have been shown to cause CVID-like phenotypes. Among these, LRBA deficiency and CTLA-4 haploinsufficiency in particular are clinically important as special CVID subtypes in which autoimmunity and organ involvement complications are prominent together with B-cell dysfunction.

CVID and IgA deficiency show genetic continuity, and the two diseases sometimes coexist within the same family. This suggests that a shared genetic predisposition is expressed as different antibody deficiency phenotypes. The HLA-A1-B8-DR3 haplotype has been reported to be associated with both CVID and IgA deficiency.

3. Genetics

CVID is a genetically very heterogeneous group of diseases, and a single-gene cause is identified in only about 10–20% of all cases. Most of the rest are regarded as the combined result of a polygenic predisposition and environmental factors. Among CVID cases with an identified single-gene cause, the genes drawing the most attention are as follows.

TNFRSF13B (TACI gene, 17p11.2): TACI (transmembrane activator and CAML interactor) is a receptor important for B-cell survival and class switching. TACI variants (especially C104R, A181E) are found in about 8–10% of CVID patients. Interestingly, the same variants are sometimes found in healthy family members, suggesting that TACI variants act as risk factors rather than causing CVID on their own. TNFRSF13C (BAFF-R gene, 22q13.2): BAFF receptor deficiency causes impaired B-cell development and hypogammaglobulinemia and shows a CVID-like phenotype. ICOS (2q33.2): involved in costimulatory signaling of activated T cells; in ICOS deficiency the germinal center reaction is impaired, resulting in poor production of switched memory B cells and IgG. LRBA (4q31.3): lysosome-associated vesicle-binding protein 1; in LRBA deficiency, intracellular degradation of CTLA-4 protein increases, producing a CVID-like phenotype with T-cell hyperactivation, autoimmunity and lymphoproliferative complications. CTLA-4: immune dysregulation and CVID-like antibody deficiency also occur in CTLA-4 haploinsufficiency.

The mode of inheritance of CVID varies with the causative gene. ICOS deficiency is autosomal recessive, LRBA deficiency is autosomal recessive and CTLA-4 haploinsufficiency is autosomal dominant, while TACI variants show a complex mode of inheritance with low complete penetrance. Whole-exome or whole-genome sequencing (WES/WGS) is used to identify single-gene causes, and gene identification is important for determining the direction of treatment (e.g., abatacept is effective in LRBA/CTLA4 abnormalities).

4. General epidemiology

CVID is clinically the most common of the primary antibody deficiencies, with a worldwide prevalence estimated at about 1 in 25,000–50,000. This is the prevalence of CVID as a whole (including D83.0–D83.9), and the D83.0 subtype, the group of patients with prominent abnormalities of B-cell numbers and function, accounts for a considerable portion of all CVID. Relatively high prevalence is reported in populations of European ancestry, but it also occurs worldwide in non-European populations.

A characteristic feature of the age-of-onset distribution of CVID is its bimodal form: the first peak is in adolescence at 10–15 years, and the second and more common peak is in adulthood at 20–35 years. Patients diagnosed in the second peak make up the majority, and the mean age at diagnosis is about 30 years. However, most cohort studies confirm an average delay of 5–10 years from the onset of clinical symptoms to diagnosis. Because this diagnostic delay causes irreversible organ complications, including lung damage (bronchiectasis), active screening of adults with recurrent infections is emphasized.

The sex distribution is almost equal (male:female ratio about 1:1), with no tendency toward a particular sex. Familial occurrence (familial CVID) is reported in about 10% of all cases, and CVID and IgA deficiency are sometimes observed together within the same family. Epidemiological data in Korea are limited, but the diagnostic rate is gradually improving with increased care by immunology specialists and the widespread use of serum Ig testing.

5. Pathophysiology

The core pathophysiology of D83.0 (CVID with abnormalities of B-cell numbers and function) is impaired B-cell differentiation and maturation. Normally, B cells develop in the bone marrow from precursor B cells → immature B cells → naive B cells, and then, interacting with follicular helper T cells (Tfh) in the germinal centers of peripheral lymphoid organs (lymph nodes, spleen, tonsils), undergo the processes of ① somatic hypermutation → selection of high-affinity antibodies, ② class-switch recombination → production of IgG and IgA, ③ plasma cell differentiation and ④ memory B cell formation.

In D83.0 patients, among these processes the generation of class-switched memory B cells is particularly markedly impaired, so switched memory B cells (CD27+IgD−IgM−) are markedly reduced in peripheral blood and secondary lymphoid organs. This memory B-cell deficiency leads to insufficient IgG and IgA responses to T cell-dependent antigens, and antigen-specific IgG titers after vaccination are low or not formed. Patients in whom the B-cell number itself is reduced are also included; in such cases, dysfunction of receptors involved in B-cell precursor development or maintenance of peripheral B-cell survival (BAFF-R, CD19-CD21 complex, etc.) is presumed to be the cause.

T cells are numerically normal in most D83.0 patients, but Tfh cell dysfunction may accompany it. In ICOS deficiency, Tfh cell differentiation itself is impaired and the germinal center reaction becomes insufficient. Thus, the pathophysiology of D83.0 can result from intrinsic B-cell developmental defects, insufficient T-cell help or a complex mechanism combining both. Impairment of the final stage of differentiation of B cells into plasma cells ultimately results in failure of antibody production.

The most important clinical consequence of antibody deficiency is impaired defense against encapsulated bacteria (Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, etc.). These bacteria evade phagocytosis with their surface polysaccharide capsule, so specific opsonizing IgG antibodies against it are essential for mediating phagocytosis by neutrophils and macrophages. When these antibodies are deficient in CVID, the mucosa of the upper airway (sinuses, middle ear) and lower airway (lungs) is exposed to recurrent bacterial infections.

6. Symptoms

The clinical symptoms of CVID D83.0 are broadly divided into infectious complications due to immunoglobulin deficiency and non-infectious inflammatory complications.

Recurrent sinopulmonary infection is the most common and characteristic symptom. Recurrent bacterial sinusitis, otitis media, bronchitis and pneumonia occur 2 or more times a year; they respond to standard antibiotic treatment but recur repeatedly. Pneumonia is often caused by encapsulated bacteria, and even after treatment, damage to the lung parenchyma accumulates and bronchiectasis develops. Bronchiectasis is found in about 25–50% of CVID patients and creates a vicious cycle of declining lung function and chronic respiratory infection. In chronic airway infection, Pseudomonas aeruginosa, nontuberculous mycobacteria (NTM) and others also become a problem.

Gastrointestinal complications are also an important group of symptoms. Chronic diarrhea, malabsorption and weight loss can occur, and Giardia lamblia infection is particularly common in CVID and tends to become chronic. Intestinal infections such as Campylobacter are also frequent. Some patients develop inflammatory bowel disease (IBD)-like symptoms (abdominal pain, bloody stools, abdominal cramps), and intestinal mucosal biopsy shows inflammatory findings of unknown cause. CVID enteropathy is an intestinal lesion intrinsic to CVID that can cause digestive and absorptive impairment and nutritional deficiencies.

Among non-infectious complications, autoimmune phenomena are common. Immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), systemic lupus erythematosus and rheumatoid arthritis-like symptoms can occur. Granulomatous lesions (sarcoidosis-like non-infectious granulomas in the lungs, spleen, lymph nodes, liver and skin) also appear in some patients; they are difficult to diagnose and sometimes respond poorly to treatment. The risk of malignancy is increased, and in particular the risk of non-Hodgkin lymphoma and gastric cancer (related to H. pylori infection) is higher than in the general population.

7. Signs

The physical and laboratory signs of CVID D83.0 are central to the diagnosis.

Reduced serum immunoglobulins: IgG < 5 g/L (or 2 standard deviations or more below the normal mean for age) + reduced IgA and/or IgM is the first criterion for diagnosis. Reduced IgG is the most consistent finding, together with reduced IgA alone or IgA+IgM. Poor antibody response after vaccination: it is characteristic that antibody titers do not rise 4-fold or more 4 weeks after pneumococcal polysaccharide vaccine (PPV23) or protein conjugate vaccine (PCV), or fail to reach target titers (≥1.3 μg/mL for ≥50% of serotypes).

B-cell immunophenotype: On flow cytometry, a marked reduction in the fraction of switched memory B cells (CD27+IgD−IgM−) (<2% of CD19+ B cells) is the characteristic immunological finding of D83.0. The total B-cell count (CD19+) itself may be reduced or within the normal range. Naive B cells (CD27−IgD+) are normal or increased. The number of plasmablasts (CD19+CD27++CD38++) is also reduced.

Physical findings: Lymphadenopathy (reactive lymphadenopathy or lymphoma) and splenomegaly are frequent. In chronic airway infection, crackles on auscultation and an obstructive or mixed ventilatory defect on pulmonary function testing may appear. Chest CT confirms bronchiectasis, bronchial wall thickening and bronchiolitis. With intestinal malabsorption, weight loss, edema and anemia are observed.

8. Screening

Screening for CVID begins on the basis of clinical symptoms and proceeds with stepwise serum testing. Active serum immunoglobulin testing is recommended in the following clinical situations: ① 2 or more serious bacterial infections (pneumonia, sinusitis) per year in adults, ② infections at atypical sites (arthritis or meningitis due to encapsulated bacteria), ③ chronic diarrhea + Giardia infection, ④ bronchiectasis (of unknown cause) on sinus or lung CT, ⑤ recurrent infections persisting despite vaccination.

First-line screening: Quantitative testing of serum IgG, IgA and IgM is most important. All three Ig classes are measured simultaneously to confirm reduced IgG together with accompanying reductions in IgA and IgM. CVID is likely when IgG < 5 g/L and one or more of IgA or IgM is reduced.

Second-line screening: Measurement of antibody titers after vaccination (4 weeks after pneumococcal or tetanus toxoid vaccination). Peripheral blood B-cell fractions (CD19+ and CD27+IgD−IgM− switched memory B cells). Family history investigation (identification of familial CVID or family members with IgA deficiency).

Exclusion of secondary causes: Tests are performed for protein-losing enteropathy (albumin, fecal alpha-1-antitrypsin), nephrotic syndrome (proteinuria), lymphoma and hematologic malignancies (blood count, LDH, protein electrophoresis), drug induction (gold, sulfasalazine, carbamazepine, penicillamine) and HIV infection.

9. Diagnosis

The diagnosis of CVID D83.0 applies the ESID (revised 2016) or ICON (2016) criteria.

CVID diagnostic criteria (ESID 2016): ① marked reduction of IgG (at least 2 SD below the normal mean for sex and age, or IgG < 5 g/L, although this value is not necessarily an absolute criterion); ② reduced IgA and/or IgM; ③ poor antibody response to vaccination (protein conjugate or polysaccharide vaccines); ④ onset after age 4; ⑤ exclusion of secondary causes; ⑥ confirmation of reduced or present B cells (differentiation from agammaglobulinemias such as XLA). In D83.0, reduced B-cell numbers or a marked reduction of switched memory B cells is confirmed immunologically.

Additional assessment of immune function: Peripheral blood T-cell, B-cell and NK-cell fractions; quantification of switched memory B cells (CD27+IgD−IgM−); T-cell function tests (proliferative responses). To exclude or confirm a single-gene cause, NGS testing including a CVID-related gene panel (ICOS, TACI, BAFF-R, CD19, LRBA, CTLA-4, etc.) is performed. Chest CT (assessment of the extent of bronchiectasis), upper gastrointestinal endoscopy and colonoscopy (assessment of gastrointestinal complications) and PET-CT (when granuloma or lymphoma is suspected) are performed according to the clinical situation.

Differential diagnosis: Differentiation is needed from X-linked agammaglobulinemia (XLA, BTK variants, almost no B cells), specific antibody deficiency (SAD, normal IgG but no specific antibody response), hyper-IgM syndrome (elevated IgM + reduced IgG/IgA), thymoma-associated hypogammaglobulinemia, IgA deficiency and drug-induced antibody deficiency.

10. Treatment

The mainstay of CVID treatment is immunoglobulin replacement therapy (IgG replacement therapy), with treatment of complications added around it.

IgG replacement therapy: Intravenous immunoglobulin (IVIG, injections at 3–4-week intervals) or subcutaneous immunoglobulin (SCIG, self-administered subcutaneous injections once or twice a week) is the standard treatment. The target IgG maintenance level is ≥700–800 mg/dL in the absence of underlying infectious complications, and when there are chronic pulmonary complications such as pneumonia or bronchiectasis, a target of ≥1,000 mg/dL or more is recommended. Compared with IVIG, SCIG has the advantages of not requiring venous access, allowing self-administration, and providing sustained maintenance of serum IgG with less peak/trough fluctuation. Recurrent bacterial infections, the main cause of death in CVID patients before the introduction of IVIG, have been greatly reduced by IgG replacement therapy.

Infection management: Appropriate antibiotics are given promptly for acute infectious episodes. When bronchiectasis has progressed, long-term prophylactic antibiotics (azithromycin 3 times/week or doxycycline), postural drainage and inhaled mucolytic therapy are used. When chronic Pseudomonas airway infection is confirmed, antipseudomonal antibiotics and inhaled antibiotics are considered.

Treatment of non-infectious complications: For autoimmune phenomena (ITP, AIHA), steroids, IVIG, rituximab and lupatinib (thrombopoietin receptor agonist for ITP) are applied depending on the situation. Abatacept (a CTLA-4 Ig fusion protein) has been reported to be effective for autoimmune and lymphoproliferative complications arising in LRBA deficiency or CTLA-4 haploinsufficiency. For granulomatous complications, steroids, azathioprine, cyclosporine, rituximab and TNF inhibitors are used in combination. When malignant lymphoma develops, standard chemotherapy or HSCT is performed.

11. Prognosis

Before the introduction of IVIG (1980s), the main cause of death in CVID patients was severe bacterial infection (pneumonia, sepsis), and survival was greatly shortened. Since the introduction of IgG replacement therapy, overall survival of CVID patients has improved markedly, and the 5-year survival of CVID patients currently receiving IVIG treatment is over 90%.

However, there are factors that determine the long-term prognosis. When chronic lung disease including bronchiectasis develops early, progressive decline in lung function increases morbidity and mortality. IVIG treatment sometimes does not completely prevent the progression of bronchiectasis, and decline in lung function remains a major cause of chronic morbidity in CVID. The risk of malignancy (non-Hodgkin lymphoma, gastric cancer, colorectal cancer) is increased compared with the general population, and lymphoma is an important cause of death. The prognosis is relatively poor when autoimmune complications (ITP, AIHA, enteritis) and granulomatous complications are present. The longer the diagnostic delay (on average 5–10 years), the more often irreversible complications such as bronchiectasis have already progressed at the time of diagnosis, so early diagnosis and early initiation of IVIG are key to improving long-term prognosis.

12. Prevention

Prevention of CVID consists mainly of secondary and tertiary prevention that suppress the development and progression of complications. Because in most cases there is no single-gene cause, genetic primary prevention is limited.

Secondary prevention: IgG replacement therapy (IVIG or SCIG) is started immediately upon diagnosis to prevent recurrent infections and delay the development of bronchiectasis. Inactivated vaccines (pneumococcal, influenza, hepatitis B, tetanus-diphtheria vaccines) are given regularly, bearing in mind that the immune response may be incomplete. Live vaccines (measles-mumps-rubella, varicella, nasal spray influenza, oral polio, BCG, yellow fever) are absolutely contraindicated. Before childbirth, school entry or travel, patients must be informed of the contraindication to live vaccines along with the need for vaccinations.

Prevention of pulmonary complications: Regular (every 6–12 months) pulmonary function tests and chest CT are performed for early detection of progression of bronchiectasis. When bronchiectasis is confirmed, the target IgG level is raised and prophylactic antibiotic therapy is added. Smoking accelerates pulmonary complications in CVID, so smoking cessation is essential.

Monitoring for malignancy and autoimmunity: Regular assessment for lymphadenopathy, night sweats and weight loss (symptoms suggesting lymphoma), platelet and blood count abnormalities (autoimmune cytopenias), and abdominal pain and bloody stools (intestinal complications). Upper gastrointestinal endoscopy (H. pylori screening and gastric cancer surveillance) is performed periodically. When a single-gene cause (LRBA, CTLA-4, etc.) has been identified, genetic counseling and family screening are performed. Patient education (self-administration of IVIG, early response to infection, emergency department visits in crisis situations) and long-term follow-up at a specialized immunology clinic are essential for managing the long-term prognosis of CVID.


13. References

  1. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Clinical Immunology. 1999;93(3):190–197. DOI: 10.1006/clim.1999.4799. PMID: 10600329.

  2. Warnatz K, Denz A, Dräger R, et al. Severe deficiency of switched memory B cells (CD27+IgM−IgD−) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood. 2002;99(5):1544–1551. DOI: 10.1182/blood.V99.5.1544. PMID: 11861264.

  3. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2):277–286. DOI: 10.1182/blood-2007-11-124545. PMID: 18319398.

  4. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clinical Immunology. 1999;92(1):34–48. DOI: 10.1006/clim.1999.4725. PMID: 10413651.

  5. Oksenhendler E, Gérard L, Fieschi C, et al. Infections in 252 patients with common variable immunodeficiency. Clinical Infectious Diseases. 2008;46(10):1547–1554. DOI: 10.1086/587669. PMID: 18419489.

  6. Grimbacher B, Hutloff A, Schlesier M, et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nature Immunology. 2003;4(3):261–268. DOI: 10.1038/ni902. PMID: 12577056.

  7. Lo B, Zhang K, Lu W, et al. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349(6246):436–440. DOI: 10.1126/science.aaa1663. PMID: 26206937.

  8. Seidel MG, Kindle G, Gathmann B, et al. The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. Journal of Allergy and Clinical Immunology: In Practice. 2019;7(6):1763–1770. DOI: 10.1016/j.jaip.2019.02.004. PMID: 30776527.

  9. Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. Journal of Allergy and Clinical Immunology: In Practice. 2016;4(1):38–59. DOI: 10.1016/j.jaip.2015.07.025. PMID: 26563668.

  10. Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. Journal of Clinical Immunology. 2018;38(1):96–128. DOI: 10.1007/s10875-017-0464-9. PMID: 29226301.